Rigel Pharmaceuticals Inc (RIGL)
Rigel Announces Availability of VEPPANU™(vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Rigel Announces Availability of VEPPANU™(vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
📈 **POSITIVE** • High confidence analysis (83%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical